Royal Philips and BioIntelliSense are set to receive about $2.8m funding from the US Department of Defense (DoD) to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of symptoms related to Covid-19.

BioIntelliSense Announces FDA Clearance of the BioSticker™, the First  Single-Use Medical Device Enabling 30 Days of Continuous Vital Signs  Monitoring

The US Army Medical Research and Development Command (USAMRDC) has selected the companies to receive the funding.

The companies will get the funding through a Medical Technology Enterprise Consortium (MTEC) award.

It aims to speed up the usage of wearable diagnostics that would benefit military and public health through the early detection and containment of pre-symptomatic Covid-19 cases.

Working with the University of Colorado Anschutz Medical Campus, the clinical study will have 2,500 eligible subjects with a recent, known exposure to Covid-19 and/or early symptoms of the disease.

As part of the study, BioIntelliSense’s medical grade wearable BioSticker will be validated for early detection of Covid-like symptoms.

The research will also focus on the assessment of scalability, reliability, software interface and user environment testing.

Philips North America chief market leader and executive committee member Vitor Rocha said: “To turn the tide on Covid-19, the public and private sectors need to use every available tool in their arsenal, which includes looking at new ways of how we can create solutions for early disease detection.